S&P 500 cuts losses as Nvidia climbs ahead of results
Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a $1.47 billion market cap biotech company, saw its President and CEO Kevin Koch sell 7,972 shares of common stock on August 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at an average price of $13.3924, with prices ranging from $13.36 to $13.49, for a total transaction value of $106,764. The transaction comes as the stock has gained over 7.5% in the past week, despite being down 45% over the last six months. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt on its balance sheet.
On the same day, Koch exercised options to acquire 17,968 shares of Edgewise Therapeutics common stock at a price of $0. Additionally, Koch was granted 87,500 Restricted Stock Units and options to purchase 525,000 shares of common stock. While five analysts have recently revised their earnings estimates upward, InvestingPro subscribers can access comprehensive insider trading patterns and 8 additional key insights about EWTX’s valuation and growth prospects through the Pro Research Report.
In other recent news, Edgewise Therapeutics reported a narrower-than-expected loss for the second quarter of 2025. The company posted a quarterly loss of $0.34 per share, surpassing analysts’ expectations of a $0.42 per share loss. Edgewise maintained a robust cash position with approximately $594 million as of June 30, 2025, supporting its ongoing clinical programs. Analysts from RBC Capital raised their price target for Edgewise Therapeutics to $49, while maintaining an Outperform rating, following the company’s earnings report. Raymond James also reiterated a Strong Buy rating with a $46 price target, emphasizing that key catalysts remain on schedule. Both firms highlighted the anticipated results from the EDG-7500 Phase 2 CIRRUS-HCM Part D trial expected in the fourth quarter of 2025. Earlier trial data showed promising efficacy, although concerns were noted about a potential atrial fibrillation signal in 14% of patients. These developments reflect continued interest and analysis from the investment community regarding Edgewise Therapeutics’ progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.